7E14 image
Deposition Date 2021-01-30
Release Date 2021-07-07
Last Version Date 2024-03-27
Entry Detail
PDB ID:
7E14
Title:
Compound2_GLP-1R_OWL833_Gs complex structure
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Bos taurus (Taxon ID: 9913)
Rattus norvegicus (Taxon ID: 10116)
synthetic construct (Taxon ID: 32630)
Method Details:
Experimental Method:
Resolution:
2.90 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Gs
Chain IDs:A
Chain Length:246
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:B
Chain Length:345
Number of Molecules:1
Biological Source:Bos taurus
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:G protein
Chain IDs:C (auth: G)
Chain Length:71
Number of Molecules:1
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Molecule:Nb35
Chain IDs:D (auth: N)
Chain Length:128
Number of Molecules:1
Biological Source:synthetic construct
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glucagon-like peptide 1 receptor
Gene (Uniprot):GLP1R
Chain IDs:E (auth: R)
Chain Length:440
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
Nat Commun 12 3763 3763 (2021)
PMID: 34145245 DOI: 10.1038/s41467-021-24058-z

Abstact

The glucagon-like peptide-1 (GLP-1) receptor is a validated drug target for metabolic disorders. Ago-allosteric modulators are capable of acting both as agonists on their own and as efficacy enhancers of orthosteric ligands. However, the molecular details of ago-allosterism remain elusive. Here, we report three cryo-electron microscopy structures of GLP-1R bound to (i) compound 2 (an ago-allosteric modulator); (ii) compound 2 and GLP-1; and (iii) compound 2 and LY3502970 (a small molecule agonist), all in complex with heterotrimeric Gs. The structures reveal that compound 2 is covalently bonded to C347 at the cytoplasmic end of TM6 and triggers its outward movement in cooperation with the ECD whose N terminus penetrates into the GLP-1 binding site. This allows compound 2 to execute positive allosteric modulation through enhancement of both agonist binding and G protein coupling. Our findings offer insights into the structural basis of ago-allosterism at GLP-1R and may aid the design of better therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback